방사선의학 웹진

바로가기  >

Abstract
We aimed to quantitatively and qualitatively assess whether there is a discrepancy in detecting amyloid beta (Aβ) positivity between 18F-florbetaben (FBB) and 18F-flutemetamol (FMM) positron emission tomography (PET). We obtained paired FBB and FMM PET images from 107 participants. Three experts visually quantified the Aβ deposition as positive or negative. Quantitative assessment was performed using global cortical standardized uptake value ratio (SUVR) with the whole cerebellum as the reference region. Inter-rater agreement was excellent for FBB and FMM. The concordance rates between FBB and FMM were 94.4% (101/107) for visual assessment and 98.1% (105/107) for SUVR cut-off categorization. Both FBB and FMM showed high agreement rates between visual assessment and SUVR positive or negative categorization (93.5% in FBB and 91.2% in FMM). When the two ligands were compared based on SUVR cut-off categorization as standard of truth, although not statistically significant, the false-positive rate was higher in FMM (9.1%) than in FBB (1.8%) (p = 0.13). Our findings suggested that both FBB and FMM had excellent agreement when used to quantitatively and qualitatively evaluate Aβ deposits, thus, combining amyloid PET data associated with the use of different ligands from multi-centers is feasible.

Affiliations

Soo Hyun Cho  1   2 , Yeong Sim Choe  1   3   4 , Young Ju Kim  1   4 , Byungju Lee  5 , Hee Jin Kim  1   4 , Hyemin Jang  1   4 , Jun Pyo Kim  1   4 , Young Hee Jung  6 , Soo-Jong Kim  1   3   4 , Byeong C Kim  2 , Gill Farrar  7 , Duk L Na  1   3   4   8 , Seung Hwan Moon  9 , Sang Won Seo  10   11   12   13   14
1 Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
2 Department of Neurology, Chonnam National University Medical School, Chonnam National University Hospital, Gwangju, Korea.
3 Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea.
4 Neuroscience Center, Samsung Medical Center, Seoul, Korea.
5 Department of Neurology, Yuseong Geriatric Rehabilitation Hospital, Pohang, Korea.
6 Department of Neurology, Myoungji Hospital, Hanyang University, Goyangsi, Korea.
7 Pharmaceutical Diagnostics, GE Healthcare, Chalfont St Giles, UK.
8 Stem Cell and Regenerative Medicine Institute, Samsung Medical Center, Seoul, Korea.
9 Department of Nuclear Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea. shmoon0914@gmail.com.
10 Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. sw72.seo@samsung.com.
11 Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea. sw72.seo@samsung.com.
12 Neuroscience Center, Samsung Medical Center, Seoul, Korea. sw72.seo@samsung.com.
13 Samsung Alzheimer Research Center, Samsung Medical Center, Seoul, Korea. sw72.seo@samsung.com.
14 Department of Intelligent Precision Healthcare Convergence, Sungkyunkwan University School of Medicine, Suwon, Korea. sw72.seo@samsung.com.